Compare Stocks

→ Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGE AgeX Therapeutics		$3.67	$11.07 ▼ $35.71	$11.99M	1.18	3,849 shs	3,700 shs
TORC resTORbio	$1.88 -10.9%	$12.16	$0.86 ▼ $10.50	$68.35M	2.43	1.15 million shs	1.48 million shs
VBLT Vascular Biogenics	$5.46 -8.8%	$0.40	$0.10 ▼ $6.74	$423.91M	0.77	2.19 million shs	161,505 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGE AgeX Therapeutics	0.00%	0.00%	-11.90%	+4,340.00%	+2,632.31%
TORC resTORbio	0.00%	-4.11%	-4.55%	-14.98%	-65.63%
VBLT Vascular Biogenics	0.00%	0.00%	0.00%	0.00%	+3,207.09%

Claim Your Complimentary Bitcoin Reward (Ad)

Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.

Secure Your Spot Now

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGE AgeX Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TORC resTORbio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VBLT Vascular Biogenics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGE AgeX Therapeutics	N/A	N/A	N/A	N/A
TORC resTORbio	N/A	N/A	N/A	N/A
VBLT Vascular Biogenics	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGE AgeX Therapeutics	$140K	0.00	N/A	N/A	($16.07) per share	0.00
TORC resTORbio	N/A	N/A	N/A	N/A	$2.24 per share	N/A
VBLT Vascular Biogenics	$660K	642.29	N/A	N/A	$0.32 per share	17.06

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGE AgeX Therapeutics	-$14.80M	-$13.03	N/A	N/A	N/A	-10,424.65%	N/A	-120.90%	5/13/2024 (Estimated)
TORC resTORbio	-$82.74M	-$2.41	N/A	N/A	N/A	N/A	-78.12%	-71.63%	N/A
VBLT Vascular Biogenics	-$32.30M	-$0.21	N/A	∞	N/A	N/A	-73.45%	-54.11%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGE AgeX Therapeutics	N/A	N/A	N/A	N/A	N/A
TORC resTORbio	N/A	N/A	N/A	N/A	N/A
VBLT Vascular Biogenics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGE AgeX Therapeutics	N/A	0.13	0.36
TORC resTORbio	N/A	20.69	20.69
VBLT Vascular Biogenics	N/A	4.63	4.63

Ownership

Institutional Ownership

Company	Institutional Ownership
AGE AgeX Therapeutics	12.50%
TORC resTORbio	46.19%
VBLT Vascular Biogenics	0.96%

Insider Ownership

Company	Insider Ownership
AGE AgeX Therapeutics	6.50%
TORC resTORbio	11.80%
VBLT Vascular Biogenics	6.13%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AGE AgeX Therapeutics	5	1.08 million	1.01 million	Not Optionable
TORC resTORbio	N/A	36.45 million	N/A	Not Optionable
VBLT Vascular Biogenics	7	77.64 million	72.88 million	Optionable

TORC, AGE, and VBLT Headlines

Source	Headline
	Tommy Garten elected to VBL Hall of Fame therecorderonline.com - March 28 at 1:31 PM
	Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system nature.com - February 21 at 3:29 PM
	Vascular News and Research news-medical.net - November 25 at 2:28 PM
	Vascular Biogenics (VBLT) Price Target Increased by 160.00% to 13.26 msn.com - November 3 at 12:39 AM
	Notable Labs Closes Merger Transaction With VBL Therapeutics finance.yahoo.com - October 16 at 3:55 PM
	VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting finance.yahoo.com - October 12 at 3:13 PM
	VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting finance.yahoo.com - October 4 at 8:40 AM
	Vascular Biogenics Rises on Presentation Hype finance.yahoo.com - September 9 at 12:00 PM
	VBLT Stock Sees Decline of Approximately -0.22% in Last Five Days knoxdaily.com - September 7 at 9:15 PM
	VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC finance.yahoo.com - September 6 at 7:30 PM
	VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT businesswire.com - August 28 at 7:00 PM
	VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT businesswire.com - August 28 at 3:04 PM
	VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update finance.yahoo.com - August 14 at 8:09 AM
	Monitoring Vascular Biogenics Ltd. (VBLT) after recent insider movements knoxdaily.com - July 26 at 4:10 PM
	Vascular Biogenics (NASDAQ: VBLT) fool.com - July 23 at 5:52 PM
	Recent Insider Activity Suggests Potential Gains for Vascular Biogenics Ltd. (VBLT) knoxdaily.com - July 12 at 4:20 PM
	VBLT Stock Sees Decline of Approximately -4.31% in Last Five Days knoxdaily.com - July 7 at 2:11 PM
	Days-to-cover ratio for VBLT surges to 0.84 due to rise in short interest knoxdaily.com - June 23 at 8:26 PM
	The Role of Peripheral Arterial Disease in the Pathogenesis of Diabetic Foot Disease: When to Refer for Vascular Surgery medscape.com - May 18 at 1:35 AM
	VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update finance.yahoo.com - May 15 at 8:03 PM
	Developing a Patient-Centered Approach to Vascular Access Device Selection medscape.com - May 10 at 8:52 AM
	CADASIL: The Most Common Hereditary Subcortical Vascular Dementia medscape.com - May 5 at 1:05 AM
	Aspirin in Stroke Prevention in Nonvalvular Atrial Fibrillation and Stable Vascular Disease medscape.com - May 2 at 8:00 PM
	Vascular Biogenics Stock (NASDAQ:VBLT), Dividends benzinga.com - April 4 at 1:52 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
5 Stocks in the Current Bull Market with Upside to Come
April 5, 2024 10:14 AM
View 5 Stocks in the Current Bull Market with Upside to Come
Hasbro’s Management Made All the Right Calls This Quarter
April 25, 2024 11:16 AM
View Hasbro’s Management Made All the Right Calls This Quarter
2 Data Storage Device Stocks Thriving From the AI Boom
April 2, 2024 7:25 AM
View 2 Data Storage Device Stocks Thriving From the AI Boom
You Can Follow BlackRock’s Market View for Your Money
April 12, 2024 10:00 AM
View You Can Follow BlackRock’s Market View for Your Money

All Headlines

Company Descriptions

AgeX Therapeutics

NYSE:AGE

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.

resTORbio

NASDAQ:TORC

Adicet Bio, Inc. is a biotechnology company which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Vascular Biogenics

NASDAQ:VBLT

Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial